Australia: CapVest takes step closer to winning hand of Australian IVF provider

Australia’s largest in vitro fertilization (IVF) provider, ASX-listed Virtus Health, has entered into a binding implementation deed with CapVest at the improved price of A$8.25 (US$5.92) cash per share following receipt of an updated non-binding, conditional indication of interest from BGH. The CapVest undertaking to acquire 100% at A$8.25 per share represents a premium of…